50 results about "Posterior capsular opacification" patented technology

An accommodative intraocular lens is disclosed. The lens provides multiple focuses as the result of a bi-directional shift along the eye's optical axis, and also minimizes or prevents posterior chamber opacification. The lens includes a first component which consists of an optical body and a haptic body, a second component which is structurally adapted to maintain substantial contact with the posterior surface of the capsular bag of the eye (when implanted in the eye), and a transition zone connecting the first and second components. The method of implanting the lens in the eye and the method of making the lens are also disclosed.

Ocular solutions containing at least one macrolide antibiotic and / or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial, and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the need for a subsequent surgery. The solution may be one that is invasively administered, for example, an irrigation or volume replacement solution containing at least one macrolide antibiotic such as tacrolimus, sirolimus, everolimus, cyclosporine, and ascomycin, or mycophenolic acid. The solution may be one that is non-invasively or topically administered in the form of drops, ointments, gels, creams, etc. and may include eye lubricants and contact lens solutions.

Generally, an intraocular implant and methods for treating an ocular condition. In particular, an intraocular implant which implanted between an intraocular lens and the surface of the posterior capsule of the eye inhibits migration of residual lens epithelial cells after cataract surgery by providing structural barriers to reduce posterior capsule opacification of the eye.

A thin intraocular lens for inhibiting posterior capsular opacification (PCO) includes an optic having a sharp edge which extends posteriorly and between a posterior concave region and an outer-most peripheral edge surface that extends parallel to the optical axis.

Ocular solutions containing at least one macrolide antibiotic and / or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial, and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the need for a subsequent surgery. The solution may be one that is invasively administered, for example, an irrigation or volume replacement solution containing at least one macrolide antibiotic such as tacrolimus, sirolimus, everolimus, cyclosporine, and ascomycin, or mycophenolic acid. The solution may be one that is non-invasively or topically administered in the form of drops, ointments, gels, creams, etc. and may include eye lubricants and contact lens solutions. The solution may contain a supratherapeutic concentration of agent(s) so that a therapeutic concentration of a topically administered solution accumulates in a diseased ocular structure sufficient to treat the disease. The agent(s) may be formulated with polymers or other components for extended or slow release to provide a substantially constant concentration over the course of treatment.

Generally, an intraocular implant and methods for treating an ocular condition. In particular, an intraocular implant which implanted between an intraocular lens and the surface of the posterior capsule of the eye inhibits migration of residual lens epithelial cells after cataract surgery by providing structural barriers to reduce posterior capsule opacification of the eye.

The invention provides a method to treat or prevent posterior capsular opacification. The method comprises administering a therapeutically or prophylactically effective amount of a pharmaceutical composition comprising at least one kinase inhibitor. The kinase inhibitor inhibits p38 kinases, ERK kinases, and / or Src family kinases. The invention also provides an ocular device coated with at least one kinase inhibitor.

Ocular solutions containing at least one macrolide antibiotic and / or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial, and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the need for a subsequent surgery. The solution may be one that is invasively administered, for example, an irrigation or volume replacement solution containing at least one macrolide antibiotic such as tacrolimus, sirolimus, everolimus, cyclosporine, and ascomycin, or mycophenolic acid. The solution may be one that is non-invasively or topically administered in the form of drops, ointments, gels, creams, etc. and may include eye lubricants and contact lens solutions. The solution may contain a supratherapeutic concentration of agent(s) so that a therapeutic concentration of a topically administered solution accumulates in a diseased ocular structure sufficient to treat the disease. The agent(s) may be formulated with polymers or other components for extended or slow release to provide a substantially constant concentration over the course of treatment.

An artificial lens having stents coated with antiproliferative agents for prevention and treatment of the posterior capsule opacification, the invention relates to an artificial lens having stents coating for solving problems of time of present artificial lens loaded with medicine acting on cornea is short. The artificial lens having stents coated with antiproliferative agents for prevention and treatment of the posterior capsule opacification is prepared by ordinary artificial lens and coating with antiproliferative agents, wherein the coating with antiproliferative agents adheres on surface of ordinary artificial lens, thickness of the coating is 3 to 20 mum. The invention adopts macomolecule coating material to coat antiproliferative agents on artificial lens, slowly releases agents in capsules and ambitus cells, represses generation of lens epithelial cell, prevents and cures formation of the posterior capsule opacification. The agents of the invention act on cornea long time, capable of releasing effectively 90 to 120 days, have good therapeutic, patients use the artificial lens of the invention, formation rate of the posterior capsule opacification reduced greatly from more than 60% to 10% and without untoward reaction.

The invention relates to a posterior chamber type artificial crystal which is provided with the design of an optical part capable of improving the image quality with a highly convex rear surface. By adopting the design of highly convex surface for the optical part of the posterior chamber type artificial crystal, and by adopting the design of a high-order aspheric surface or additionally adopting the design of a composite ring curve, the distance between the rear surface of the artificial crystal optical part and a rear sac is shortened, the stability of the artificial crystal in the space position of the sac is improved, the advantage of the square edge effect on the optical part edge of the artificial crystal is enabled to be better presented, and the morbidity of PCO (posterior capsular opacification) is reduced after the artificial crystal is implanted; and since the front surface of the optical part is slightly flat, the loop of the artificial crystal (particularly the loop of one one-piece posterior chamber type artificial crystal) is enabled not to be tightly pressed onto the front surface of the optical part during folding process, the loop is more easily unfolded after being implanted into an eye, the situation of mutual adhesion between a support loop and the optical part cannot occur, and the imaging quality of the artificial crystal and / or the vision quality of an astigmia patient can be improved.

Several methods for preventing, minimizing, or delaying the incidence of posterior capsule opacification are provided. A first method involves chemically activating the surface of an implantable ocular device, such as an intraocular lens or a capsular tension ring, by grafting a chemical moiety onto the surface of the device, covalently attaching a non-cytotoxic inhibitor compound to the chemical moiety to produce an inhibitor implantable ocular device, and implanting this inhibitor implantable ocular device into the capsular bag of an eye of a patient during extracapsular cataract surgery. Appropriate inhibitor compounds include RGD mimetics, RGD peptides, and flavonoids. A second method involves surface modifying the exterior surface of a capsular tension ring by covalently attaching a mitotic inhibitor, preferably a conjugate of methotrexate and a bovine serum albumin, and implanting this inhibitor tension ring into the capsular bag of an eye of a patient during extracapsular cataract surgery. A third method involves surface modifying the exterior surface of a capsular tension ring by coating or grafting the exterior surface with a charged polyethylamine and implanting this inhibitor tension ring into the capsular bag of an eye of a patient during extracapsular cataract surgery. An implantable ocular device according to the invention, such as an intraocular lens or a capsular tension ring, contains a substrate with a chemical moiety grafted thereon and a non-cytotoxic inhibitor compound covalently bonded to the chemical moiety or contains a substrate modified with a mitotic inhibitor or charged polyethylamine. The inhibitor devices inhibits proliferation and migration of lens epithelial cells on the posterior capsule of the eye of the patient, thereby preventing, minimizing, or delaying the onset of posterior capsule opacification.

The present invention relates to method for the treatment or prevention and of proliferative eye diseases including but not limited to: age related macular degeneration associated proliferative retinopathy, proliferative diabetic retinopathy, proliferative vitreoretinopathy, posterior capsular opacification, scaring and fibrosis after glaucoma filtration surgery, uveal melanoma, and retinoblastoma. The method comprises contacting cells in the eye by means of intra-ocular injection or infusion, with a drug that irreversibly inhibits cellular proliferation without causing extensive tissue necrosis or cytotoxicity. In a preferred embodiment the drug is bizelesin.

Methods for treating post-surgical formation of cataracts or posterior capsule opacification are disclosed. The methods utilize compositions containing certain compounds having an anti-inflammatory and anti-oxidant moiety covalently linked by and amide and ester bond.

An intraoluclar refractive lens comprises an optic portion (34) with an outer peripheral edge (36) and one or more, preferably two, three or four equidistant haptic elements (38). Each haptic element (38) has the same shape, with a trapezoid or rhomboid cross-section. The edge of the outer rear surface of each haptic element (38) and the edge of the rear optic element are shaped like acute angles to prevent posterior capsular opacification.

The invention discloses an artificial crystalline lens used for preventing and / or treating posterior capsule opacification and a preparation method of the artificial crystalline lens. Trypsin is fixed on the surface of the artificial crystalline lens, namely the trypsin which has a lethal effect on crystalline lens epithelial cells is fixed on the surface of the artificial crystalline lens. Therefore, the artificial crystalline lens can selectively destroy the crystalline lens epithelial cells in a lens capsule when the artificial crystalline lens is transplanted into the lens capsule. Occurring of posterior capsular opacification is avoided.

The invention relates to a dynamic dual-mode adjustable intraocular lens and a dynamic adjusting method for human eyesight. The dynamic dual-mode adjustable intraocular lens comprises an optical part and at least two ties, wherein the optical part is made of a flexible material; and the at least two ties are peripherally and symmetrically arranged around the optical part and connected with the optical part. After the dynamic dual-mode adjustable intraocular lens is implanted in a capsular bag of an eye, the ties supported on the inner wall of a capsular bag sulcus can cause the optical facial curvature of the optical part to change under the action of tensile force of the capsular bag. The invention also relates to the dynamic adjusting method for the human eyesight by using the dynamic dual-mode adjustable intraocular lens implanted the human eye. By using the dynamic dual-mode adjustable intraocular lens and the dynamic dual-mode eyesight adjusting method, the focus adjusting range is large, the implanted incision is small, the risk of occurrence of posterior capsular opacity after intraocular lens implantation can be reduced, and complications such as shifting and eccentricity after adjustable intraocular lens surgery can be effectively reduced.

The invention provides a device for preventing and treating posterior capsule opacification. The device for preventing and treating the posterior capsule opacification comprises a container, a heat insulation pipe and an elastic membrane. An outlet end is arranged on the container. A piston which is used for squeezing out contents in the container from the output end is arranged inside the container. Two ends of the heat insulation pipe are open, wherein one end is connected with the output end of the container. The heat insulation pipe is outside sealed, the elastic membrane is arranged at the other end of the heat insulation pipe, or the elastic membrane is a test-tube-shaped elastic membrane which is arranged inside the heat insulation pipe. The test-tube-shaped elastic membrane bulges out of the heat insulation pipe to form a bubble under the action of the piston, wherein trypsin is fixed on the outer surface of the bubble which is formed by the elastic membrane. The device for preventing and treating the posterior capsule opacification can selectively remove crystalline lens epithelial cells in extracapsular cataract extraction, and therefore occurring of posterior capsular opacification is avoided.

The invention relates to new application of geldanamycin and a derivative thereof in treating and inhibiting posterior capsular opacification, belonging to the technical field of medicines. Experiments prove that a geldanamycin derivative 17AAG inhibits human lens epithelial cells from proliferating and induces lens epithelial cells to die; in an in vitro rat lens capsular bag cultivation model, 17AAG inhibits residual lens epithelial cells from proliferating, migrating and fiberizing in a lens posterior capsule greatly, induces cells with posterior capsule overgrown to die, and promotes turbid lens posterior capsule to recover transparency; in a rabbit intraocular lens replacement model, 17AAG can inhibit posterior capsular opacification. The geldanamycin and the derivative thereof inhibit posterior capsular opacification by inhibiting HSP90 molecular chaperone activity of lens cells, and have a therapeutical effect on the formed posterior capsular opacification at the same time. 17AAG has new application in treating posterior capsular opacification, and is a candidate medicine that 17AAG has development potential and can prevent and treat posterior capsular opacification.

A treatment solution used to prevent posterior capsular opacification is applied or introduced into the lens capsular bag before, during, or after cataract surgery. The treatment solution may also be applied to an intraocular lens prior to surgery. The treatment solution comprises an ion transport mechanism interference agent, which either alone or in combination with other treatment agents such as an osmotic stress agent and an agent to establish a suitable pH, selectively induces detachment and / or death of lens epithelial cells such that posterior capsular opacification is prevented. While the ion transport mechanism interference agent is capable of interfering with the cellular mechanisms and cell ion distribution of a broad range of cells, a concentration of agent is selected such that the treatment solution interferes selectively with the cellular mechanisms of lens epithelial cells while leaving other ocular cells substantially unharmed. The treatment solution selectively induces cellular death and / or detachment of lens epithelial cells while other ocular cells and tissue remain substantially unharmed and without lengthy preoperative pre-treatment.